Role of neoadjuvant chemoimmunotherapy for resectable NSCLC

被引：7

作者：

Sepesi, Boris ^{[1
]}

Swisher, Stephen G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2022年 / 19卷 / 08期

关键词：

CELL LUNG-CANCER;

D O I：

10.1038/s41571-022-00647-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial.

引用

页码：497 / 498

页数：2

共 7 条

[1] [Anonymous], 2022, CANC DISCOV
[2] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip, Enriqueta
Altorki, Nasser
Zhou, Caicun
Csoszi, Tibor
Vynnychenko, Ihor
Goloborodko, Oleksandr
Luft, Alexander
Akopov, Andrey
Martinez-Marti, Alex
Kenmotsu, Hirotsugu
Chen, Yuh-Min
Chella, Antonio
Sugawara, Shunichi
Voong, David
Wu, Fan
Yi, Jing
Deng, Yu
McCleland, Mark
Bennett, Elizabeth
Gitlitz, Barbara
Wakelee, Heather
[J]. LANCET, 2021, 398 (10308) : 1344 - 1357
[3] Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, Patrick M.
Spicer, Jonathan
Lu, Shun
Provencio, Mariano
Mitsudomi, Tetsuya
Awad, Mark M.
Felip, Enriqueta
Broderick, Stephen R.
Brahmer, Julie R.
Swanson, Scott J.
Kerr, Keith
Wang, Changli
Ciuleanu, Tudor-Eliade
Saylors, Gene B.
Tanaka, Fumihiro
Ito, Hiroyuki
Chen, Ke-Neng
Liberman, Moishe
Vokes, Everett E.
Taube, Janis M.
Dorange, Cecile
Cai, Junliang
Fiore, Joseph
Jarkowski, Anthony
Balli, David
Sausen, Mark
Pandya, Dimple
Calvet, Christophe Y.
Girard, Nicolas
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) : 1973 - 1985
[4] Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Hellmann, Matthew D.
Chaft, Jamie E.
William, William N., Jr.
Rusch, Valerie
Pisters, Katherine M. W.
Kalhor, Neda
Pataer, Apar
Travis, William D.
Swisher, Stephen G.
Kris, Mark G.
[J]. LANCET ONCOLOGY, 2014, 15 (01) : E42 - E50
[5] Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
Jiang, Juan
Wang, Yuling
Gao, Yang
Sugimura, Haruhiko
Minervini, Fabrizio
Uchino, Junji
Halmos, Balazs
Yendamuri, Sai
Velotta, Jeffrey B.
Li, Min
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 277 - +
[6] Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial
Pisters, Katherine M. W.
Vallieres, Eric
Crowley, John J.
Franklin, Wilbur A.
Bunn, Paul A., Jr.
Ginsberg, Robert J.
Putnam, Joe B., Jr.
Chansky, Kari
Gandara, David
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1843 - 1849
[7] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Wu, Yi-Long
Tsuboi, Masahiro
He, Jie
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan W.
Laktionov, Konstantin
Kim, Sang-We
Kato, Terufumi
Vu, Huu-Vinh
Lu, Shun
Lee, Kye-Young
Akewanlop, Charuwan
Yu, Chong-Jen
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Zeng, Lingmin
Hodge, Rachel
Atasoy, Ajlan
Rukazenkov, Yuri
Herbst, Roy S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18) : 1711 - 1723

← 1 →